Tell me everything on migraine for my medical conference and drug rese

Tell me everything on migraine for my medical conference and drug research

Reading File

Migraine is a broad conference and drug-research topic. A focused presentation can cover:

Definition, epidemiology, and burden
Migraine with and without aura, chronic migraine, disability, socioeconomic impact.
Neurobiology and mechanisms
Trigeminovascular activation, CGRP and PACAP signaling, cortical spreading depolarization, brainstem and hypothalamic networks.
Clinical diagnosis and differential diagnosis
ICHD-3 criteria, red flags, secondary headache exclusion, aura, vestibular and retinal migraine.
Acute treatment
NSAIDs, acetaminophen, antiemetics, triptans, gepants, ditans, ergot derivatives, emergency treatment, and medication-overuse headache.
Preventive treatment
Beta-blockers, topiramate, valproate, tricyclics, SNRIs, onabotulinumtoxinA, CGRP monoclonal antibodies, preventive gepants, and non-drug measures.
Special populations and variants
Pregnancy/lactation, pediatric and older adults, menstrual migraine, hemiplegic migraine, migraine with brainstem aura, and status migrainosus.
Drug research and pipeline
CGRP-targeted treatments, gepants, ditans, PACAP-targeted agents, biomarkers, precision medicine, comparative effectiveness, long-term safety, and access/cost issues.

High-level overview: Migraine is a recurrent neurologic disorder characterized by attacks of moderate to severe headache, typically with nausea and/or sensitivity to light and sound. It is now understood as a disorder of altered sensory processing and trigeminovascular signaling, rather than simply a vascular headache. CGRP-directed therapies have substantially changed both acute and preventive care, although treatment selection still depends on attack frequency, comorbidities, contraindications, prior treatment response, pregnancy potential, and affordability.

For drug research, the most active areas are refining CGRP-pathway therapy, evaluating long-term cardiovascular and pregnancy safety, understanding who responds to which therapy, studying medication-overuse prevention, and developing targets beyond CGRP such as PACAP.

Which section should I develop into a conference-ready, evidence-based briefing?

Tell me everything on migraine for my medical conference and drug research

Reading File

A complete migraine conference and drug-research briefing is best organized as:

Definitions and classification
- ICHD-3 diagnostic criteria
- Migraine without aura, with aura, chronic migraine
- Vestibular, menstrual, hemiplegic, retinal migraine, and migraine with brainstem aura
- Status migrainosus and persistent aura
Epidemiology and disease burden
- Prevalence by sex and age
- Disability, work loss, psychiatric and sleep comorbidity
- Progression from episodic to chronic migraine
Pathophysiology
- Trigeminovascular system
- CGRP, PACAP, substance P, glutamate, nitric oxide
- Cortical spreading depolarization and aura
- Hypothalamic, brainstem, and sensory-network involvement
Clinical assessment
- Attack phases: prodrome, aura, headache, postdrome
- Red flags for secondary headache
- Examination, when imaging is appropriate
- Differential diagnosis: tension-type headache, cluster headache, TIA, seizure, raised intracranial pressure, medication-overuse headache
Acute treatment
- NSAIDs, acetaminophen, antiemetics
- Triptans and contraindications
- Gepants: ubrogepant, rimegepant, zavegepant
- Lasmiditan
- Dihydroergotamine and emergency-department approaches
- Avoiding opioid use and medication overuse
Preventive treatment
- Traditional oral preventives: topiramate, beta-blockers, candesartan, valproate, amitriptyline, venlafaxine
- OnabotulinumtoxinA for chronic migraine
- CGRP monoclonal antibodies: erenumab, fremanezumab, galcanezumab, eptinezumab
- Preventive gepants: atogepant and rimegepant
- Choosing therapy by frequency, comorbidity, reproductive considerations, adverse effects, patient preference, and access
Non-pharmacologic care
- Trigger management, regular sleep, meals, hydration, exercise
- Cognitive behavioral therapy, biofeedback, relaxation
- Neuromodulation devices
- Headache diary and medication-overuse prevention
Special populations
- Pregnancy and lactation
- Children and adolescents
- Older adults
- Menstrual migraine
- Cardiovascular disease, renal/hepatic impairment, and psychiatric comorbidity
Drug-development and research agenda
- Comparative effectiveness of CGRP drugs versus established agents
- Long-term safety, including cardiovascular and pregnancy exposure data
- PACAP-targeted therapies and other non-CGRP targets
- Biomarkers and predictors of response
- Combination prevention and acute-treatment strategies
- Real-world adherence, cost-effectiveness, equity, and access
- Medication-overuse headache prevention and reversal

High-level conference thesis: Migraine is a neurobiological disorder of altered sensory processing and trigeminovascular signaling, not simply a vascular headache. The therapeutic shift toward CGRP-pathway treatments has improved options for both acute and preventive care, but major research gaps remain in personalized selection, long-term safety, special populations, affordability, and disease-modifying treatment.

Which focus should I build into a detailed, conference-ready evidence review: clinical management, CGRP and drug pipeline, pathophysiology, or a complete slide-style outline?

Find recent migraine guidelines and consensus statements

Reading File

Searching the Web

2024 2025 migraine clinical practice guideline consensus statement CGRP preventive acute treatment

Searching the Web

site:pubmed.ncbi.nlm.nih.gov migraine guideline consensus 2024 2025

Searching the Web

migraine guideline consensus 2024 2025 NICE European Headache Federation International Headache Society

Searching PubMed

"Migraine Disorders"[MeSH Terms] AND guideline

Searching PubMed

migraine AND consensus

Searching PubMed

"Migraine Disorders"[MeSH Terms] AND treatment

Finding Sources

Reading Article

PMID: 42673560

Reading Article

PMID: 40277319

Reading Article

PMID: 41117312

Reading Article

PMID: 39899861

Reading Article

PMID: 40096690

Reading Article

PMID: 39133176

Reading Article

PMID: 41321235

Recent migraine guidelines and consensus statements

The most relevant current documents for a medical conference or drug-research briefing are below. I have prioritized international and major society guidance from 2024-2026.

Year	Organization / document	Scope	Why it matters
2026	AAN and AHS, Pharmacologic Treatment for Migraine Prevention in Adults	Adult episodic and chronic migraine prevention	The newest major US evidence-based prevention guideline. Covers when to initiate prevention, agent selection, monitoring response and adverse effects, discontinuation, medication overuse, pregnancy/lactation, older adults, and comorbidity-based choices.
2025	Italian Society for the Study of Headache and IHS, Evidence-based guidelines for the pharmacological treatment of migraine	Acute and preventive pharmacotherapy	Broad GRADE-based guideline, including RCT evidence and expert recommendations. Particularly useful as a detailed international drug-treatment reference.
2025	AHS, Guideline update to acute treatment of migraine in adults in the emergency department	ED parenteral therapy and nerve blocks	Important update for acute severe migraine requiring emergency care. It includes pharmacologic and peripheral nerve-block evidence.
2025	IHS, Evidence-based guidelines on non-invasive neuromodulation devices	Acute and preventive device-based therapy	Reviews Cefaly, Nerivio, Relivion, gammaCore and related devices. Recommendations are generally weak because evidence certainty ranges from very low to moderate.
2025	ACP, Prevention of Episodic Migraine Headache Using Pharmacologic Treatments	Outpatient prevention in nonpregnant adults with 1-14 headache days/month	Uses benefit-harm and economic evidence. It has attracted debate because its treatment sequencing differs from the AHS position on CGRP-targeting prevention. An erratum was published.
2025	ACP, Pharmacologic Treatments of Acute Episodic Migraine Headache	Outpatient acute therapy in nonpregnant adults	Strongly recommends adding a triptan to an NSAID when NSAID treatment alone is inadequate for moderate-severe episodic migraine. It conditionally supports adding a triptan to acetaminophen when acetaminophen alone is inadequate.
2024	IHS, Global practice recommendations for acute pharmacological treatment	Acute treatment globally, including resource-limited settings	Gives both “optimal” and “essential” recommendations across 17 practical clinical questions, making it useful beyond high-income settings.
2024	AHS position statement, CGRP-targeting therapies as a first-line option for migraine prevention	CGRP monoclonal antibodies and preventive gepants	States that CGRP-targeting preventive therapies should be considered a first-line option, without requiring failure of older preventive drug classes first.
2024	French Headache Society position paper	Broad migraine management	Includes practical national guidance, including reproductive and pregnancy-related considerations.
2024	Hungarian Headache Society and Hungarian Pain Society joint guideline	Acute and chronic migraine	Includes practical care, differential diagnosis, pregnancy, and chronic migraine management.

The 2026 AAN/AHS prevention guideline

The newest major prevention guideline is the AAN/AHS prevention guideline, published in Neurology in 2026. It is especially relevant for a drug-research presentation because its evidence review includes studies through June 6, 2024 and explicitly addresses:

Indications for starting preventive medication
Choosing a preventive according to efficacy, adverse effects, patient goals, and comorbidities
Fibromyalgia, obesity, hypertension, and older age
Pregnancy, lactation, and sex-related treatment issues
Medication-overuse headache
Assessment of efficacy, adverse effects, and stopping preventive treatment

International pharmacotherapy guidance

The most useful detailed drug-treatment source is the 2025 Italian Society for the Study of Headache and International Headache Society guideline, pharmacologic migraine guideline. It used systematic review methods, Cochrane methodology, and GRADE. The authors highlight two central evidence gaps that are useful conference discussion points:

Too few head-to-head comparisons among established drugs, CGRP monoclonal antibodies, and gepants
Insufficient long-term outcome data

A concise companion document is available as the guideline summary.

Acute outpatient management

The 2025 ACP acute-treatment guideline, ACP acute guideline, applies to nonpregnant adults with episodic migraine in outpatient settings. Its key explicit recommendations are:

Add a triptan to an NSAID when moderate-severe attacks respond inadequately to NSAID therapy alone. This is a strong recommendation with moderate-certainty evidence.
Consider adding a triptan to acetaminophen when moderate-severe attacks respond inadequately to acetaminophen alone. This is conditional and based on low-certainty evidence.

For a globally applicable framework, use the IHS acute-treatment recommendations. These distinguish an optimal regimen, where broader drug access exists, from an essential regimen designed for settings with limited access to triptans, gepants, ditans, or other migraine-specific medicines.

Prevention: the major CGRP policy difference

There is an important difference between US society documents:

The 2024 AHS CGRP position statement considers CGRP-targeting therapies first-line preventive options. This includes anti-CGRP or anti-CGRP receptor monoclonal antibodies and preventive gepants.
The 2025 ACP prevention guideline evaluates clinical benefits, harms, patient values, and economic evidence for outpatient episodic-migraine prevention. Its recommendations are conditional and based on low-certainty evidence, with a more cost-conscious framework.

This difference is an excellent conference discussion topic: clinical efficacy and tolerability versus cost, evidence certainty, access, and payer-imposed step therapy. The ACP guideline has an associated erratum, so use the corrected version.

Emergency department acute migraine

The 2025 AHS ED evidence assessment, published in 2026 as AHS ED guideline update, is a major practice update. For eligible adults who require parenteral treatment:

Must offer, Level A: IV prochlorperazine and greater occipital nerve block
Must not offer, Level A: IV hydromorphone
Should offer, Level B when appropriate: IV dexketoprofen, IV ketorolac, IV metoclopramide, subcutaneous sumatriptan, and supraorbital nerve block
May offer, Level C: IV chlorpromazine, IV dexamethasone, and IV valproate
Should not offer, Level C: IV paracetamol/acetaminophen
Evidence remains insufficient for several interventions, including ketamine, lidocaine, normal saline, and sphenopalatine ganglion block.

Non-invasive neuromodulation

The 2025 IHS neuromodulation guideline reviewed 15 qualifying randomized studies. It gives weak recommendations for:

Acute treatment: SAVI Dual, Cefaly, Relivion, and Nerivio
Prevention: gammaCore Sapphire, Cefaly, and Nerivio

The panel emphasizes that devices are generally well tolerated and do not create pharmacokinetic drug-interaction concerns, but quality of evidence remains limited by small samples, sham-control and blinding challenges, and adherence issues. Use the published erratum alongside this guideline.

Suggested core reference set for your conference

If you need to limit citations to six documents, use:

Recent-evidence note: The 2025 pharmacotherapy guideline is itself a systematic review and guideline, and represents a more current synthesis than many older national treatment algorithms. It should be paired with the newer 2026 AAN/AHS prevention guideline when presenting contemporary US practice.

Best oral drug for migraine

Reading File

Finding Sources

Searching PubMed

"Migraine Disorders"[MeSH Terms] AND oral treatment

Searching the Web

2026 oral acute migraine treatment guideline triptan NSAID gepant official guideline

There is no single “best” oral migraine drug. It depends on whether you mean treating an attack or preventing future attacks.

Best oral option for a typical moderate-severe acute attack: a triptan, often rizatriptan or sumatriptan, taken early in the attack. If response is inadequate, pairing a triptan with an NSAID is often more effective. The ACP guideline specifically recommends adding a triptan to an NSAID for nonpregnant adults with moderate-severe episodic migraine not adequately relieved by an NSAID alone. ACP acute guideline
If triptans are ineffective, not tolerated, or contraindicated: oral gepants, such as ubrogepant or rimegepant, are useful non-vasoconstrictive alternatives.
Do not use triptans in established coronary/cerebrovascular disease, peripheral arterial disease, uncontrolled hypertension, or certain complicated migraine syndromes without specialist advice.
For prevention: if attacks are frequent or disabling, oral topiramate remains a common evidence-based option, but tolerability and pregnancy potential often limit it. Oral preventive gepants, especially atogepant and rimegepant, are migraine-specific alternatives. The latest AAN/AHS prevention guideline emphasizes individualized selection based on comorbidity, adverse effects, pregnancy/lactation, medication overuse, and patient preference. AAN/AHS prevention guideline

Practical bottom line:
For many otherwise healthy adults, an oral triptan plus an NSAID is the most effective standard acute regimen. If cardiovascular risk or triptan intolerance is present, an oral gepant is usually the better migraine-specific choice.

Avoid frequent rescue-drug use: triptans, gepants? Actually triptans and combination analgesics should generally be limited to fewer than 10 treatment days/month, while simple NSAIDs/acetaminophen should generally be limited to fewer than 15 days/month, to reduce medication-overuse headache risk.

Which preventive oral drug fits my patient profile?

Reading File

To match a preventive safely, I need the features that determine both benefit and contraindications.

Asking for Preferences

Which profile is closest? · How frequent are migraine days? · Any important medical issue?

This is a shared conversation. Sign in to Orris to start your own chat.